PDS Biotechnology Corp (PDSB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has a cash flow conversion efficiency ratio of -1123.053x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.37 Billion) by net assets ($3.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of PDS Biotechnology Corp to measure how much of total assets are equity-financed.
PDS Biotechnology Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PDSB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
PDS Biotechnology Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PDS Biotechnology Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RenovoRx Inc
NASDAQ:RNXT
|
-0.557x |
|
BluMetric Environmental Inc
V:BLM
|
-0.001x |
|
UNITEKNO Co.Ltd
KQ:241690
|
-0.002x |
|
Grande Portage Resources Ltd
V:GPG
|
-0.005x |
|
PTRB
KLSE:0260
|
-0.140x |
|
Enegex Ltd
AU:ENX
|
-0.061x |
|
Vissem Electronics Co. Ltd
KQ:072950
|
0.023x |
|
Kaonmedia Co Ltd
KQ:078890
|
0.033x |
Annual Cash Flow Conversion Efficiency for PDS Biotechnology Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of PDS Biotechnology Corp from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see PDS Biotechnology Corp (PDSB) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.25 Million | $-27.75 Billion | -2999.623x | -162637.71% |
| 2024-12-31 | $19.00 Million | $-35.03 Million | -1.843x | -43.19% |
| 2023-12-31 | $26.13 Million | $-33.64 Million | -1.287x | -120.31% |
| 2022-12-31 | $44.00 Million | $-25.71 Million | -0.584x | -195.79% |
| 2021-12-31 | $63.21 Million | $-12.49 Million | -0.198x | +59.24% |
| 2020-12-31 | $27.13 Million | $-13.15 Million | -0.485x | +68.63% |
| 2019-12-31 | $11.70 Million | $-18.07 Million | -1.545x | -39.06% |
| 2018-12-31 | $29.84 Million | $-33.15 Million | -1.111x | -70.28% |
| 2017-12-31 | $62.37 Million | $-40.70 Million | -0.652x | -80.97% |
| 2016-12-31 | $89.28 Million | $-32.19 Million | -0.361x | -103.01% |
| 2015-12-31 | $122.48 Million | $-21.75 Million | -0.178x | -150.89% |
| 2014-12-31 | $-27.83 Million | $-9.71 Million | 0.349x | -33.40% |
| 2013-12-31 | $-15.35 Million | $-8.04 Million | 0.524x | -21.03% |
| 2012-12-31 | $-3.38 Million | $-2.25 Million | 0.664x | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more